Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Acyl-CoA binding protein (ACBP) levels in plasma correlate with COVID-19 severity and inflammation. This finding suggests ACBP may serve as a novel biomarker for predicting disease progression and developing new therapies.
Area Of Science
- Immunology
- Molecular Biology
- Proteomics
Background
- Severe COVID-19 pathogenesis is not fully understood.
- Biomarkers predicting COVID-19 severity are needed for improved patient management and novel therapies.
- Autophagy, regulated by Acyl-CoA binding protein (ACBP), plays a role in cellular homeostasis and immune responses.
Purpose Of The Study
- To investigate the association between circulating Acyl-CoA binding protein (ACBP) levels and COVID-19 severity.
- To explore ACBP as a potential biomarker for predicting severe outcomes in COVID-19 patients.
Main Methods
- Somalogic proteomic analysis of plasma from 903 COVID-19 patients and 295 controls.
- Assessment of 5000 proteins, including ACBP, in samples collected during the acute phase of infection.
- Measurement of anti-SARS-CoV-2 IgG levels and cell-binding assays.
Main Results
- Plasma ACBP levels were significantly correlated with COVID-19 severity.
- ACBP levels were associated with inflammation and anti-SARS-CoV-2 antibody titers, independent of patient demographics and comorbidities.
- Higher ACBP levels were observed during the second COVID-19 wave in Quebec.
- ACBP levels showed a negative correlation with T and NK cell response biomarkers (IFN-γ, TNF-α, IL-21).
Conclusions
- Circulating ACBP levels represent a potential biomarker for COVID-19 severity, linked to inflammatory processes.
- Further research is warranted to elucidate the role of extracellular ACBP in immunometabolic responses during viral infections.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...